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IMPORTANCE Observational studies highlight associations of C-reactive protein (CRP), a
general marker of inflammation, and interleukin 6 (IL-6), a cytokine-stimulating CRP
production, with individual depressive symptoms. However, it is unclear whether
inflammatory activity is associated with individual depressive symptoms and to what extent
metabolic dysregulation underlies the reported associations.
OBJECTIVE To explore the genetic overlap and associations between inflammatory activity,
metabolic dysregulation, and individual depressive symptoms.
GWAS DATA SOURCES Genome-wide association study (GWAS) summary data of European
individuals, including the following: CRP levels (204 402 individuals); 9 individual depressive
symptoms (3 of which did not differentiate between underlying diametrically opposite
symptoms [eg, insomnia and hypersomnia]) as measured with the Patient Health
Questionnaire 9 (up to 117 907 individuals); summary statistics for major depression,
including and excluding UK Biobank participants, resulting in sample sizes of 500 199 and up
to 230 214 individuals, respectively; insomnia (up to 386 533 individuals); body mass index
(BMI) (up to 322 154 individuals); and height (up to 253 280 individuals).
DESIGN In this genetic correlation and 2-sample mendelian randomization (MR) study, linkage
disequilibrium score (LDSC) regression was applied to infer single-nucleotide variant–based
heritability and genetic correlation estimates. Two-sample MR tested potential causal
associations of genetic variants associated with CRP levels, IL-6 signaling, and BMI with
depressive symptoms. The study dates were November 2019 to April 2020.
RESULTS Based on large GWAS data sources, genetic correlation analyses revealed consistent
false discovery rate (FDR)–controlled associations (genetic correlation range, 0.152-0.362;
FDR P = .006 to P < .001) between CRP levels and depressive symptoms that were similar in
size to genetic correlations of BMI with depressive symptoms. Two-sample MR analyses
suggested that genetic upregulation of IL-6 signaling was associated with suicidality
(estimate [SE], 0.035 [0.010]; FDR plus Bonferroni correction P = .01), a finding that
remained stable across statistical models and sensitivity analyses using alternative instrument
selection strategies. Mendelian randomization analyses did not consistently show
associations of higher CRP levels or IL-6 signaling with other depressive symptoms, but
higher BMI was associated with anhedonia, tiredness, changes in appetite, and feelings of
inadequacy.
CONCLUSIONS AND RELEVANCE This study reports coheritability between CRP levels and
individual depressive symptoms, which may result from the potentially causal association of
metabolic dysregulation with anhedonia, tiredness, changes in appetite, and feelings of
inadequacy. The study also found that IL-6 signaling is associated with suicidality. These
findings may have clinical implications, highlighting the potential of anti-inflammatory
approaches, especially IL-6 blockade, as a putative strategy for suicide prevention.
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A ccumulating evidence implicates the immune systemin the pathogenesis of major depression (MD).1 Low-grade inflammation, as indicated by higher (>0.3 mg/dL
[>3 mg/L]) C-reactive protein (CRP) levels, is present in about
one-quarter of patients with MD and longitudinally predicts
occurrence of depressive symptoms.2,3 Results of studies4-9
have suggested specificity of the association of inflammation
and depression to a subset of depressive symptoms. C-
reactive protein and the proinflammatory cytokine interleu-
kin 6 (IL-6), an upstream stimulator of CRP production, have
been reported to be associated with increased appetite, sleep
problems, loss of energy, diurnal variation in mood, and con-
centration difficulties. However, findings vary with regard to
which inflammatory markers and depressive symptoms were
assessed and which findings were replicated.6 There is also de-
bate on the robustness of the reported associations after ad-
justment for metabolic traits, such as body mass index (BMI),
which attenuates inflammation-symptom associations.6 Such
attenuation corresponds to recent suggestions of a combined
immune-metabolic subtype of depression10 and warrants fur-
ther research to disentangle immune from metabolic associa-
tions with depressive symptoms.
Associations of inflammation with specific depressive
symptom profiles may be clinically relevant. Research sug-
gests that anti-inflammatory drugs may improve depressive
symptoms in patients with chronic inflammatory physical ill-
ness independent of improvements in physical illness.11-14 In
MD, it has been reported that immunotherapies may be help-
ful for those patients with evidence of low-grade inflamma-
tion or inflammation-associated risk factors.15,16 Informed by
these reports, several ongoing randomized clinical trials (RCTs)
are selecting patients with evidence of elevated levels of in-
flammatory proteins or based on neuroimaging markers of in-
flammation or inflammation-related symptoms (eg, work by
Khandaker et al17 and 2 other clinical trials18,19). Therefore,
identification of depressive symptoms that are associated with
inflammation is key information that may aid patient selec-
tion in future RCTs.
Genetic approaches and increasing availability of genome-
wide association study (GWAS) data may enable more fine-
grained dissection of inflammation–depressive symptom as-
sociations. Genome-wide association studies have highlighted
a polygenic architecture underlying both MD and serum CRP
levels with many single-nucleotide variants (SNVs) exhibit-
ing small associations.20,21 Such polygenic associations can be
summarized using polygenic risk scores (PRSs),22 which sum
the presence of risk alleles in individuals to create a single score.
Milaneschi and colleagues23,24 have reported that PRSs for both
increased CRP levels and BMI are associated with symptom pro-
files characteristic of atypical (increased appetite or weight)
but not typical (decreased appetite or weight) MD. However,
it remains unclear from these analyses if symptoms other than
changes in appetite or weight underlie the CRP–atypical MD
association and whether this association is potentially causal
or arising from metabolic factors.
Linkage disequilibrium score (LDSC) regression25,26 and
mendelian randomization (MR)27 analyses could further dis-
sect the associations between inflammation, metabolic
factors, and depressive symptoms. Linkage disequilibrium
score regression allows assessment of SNV-based phenotype
heritability and coheritability between 2 traits. Mendelian ran-
domization analyses enable an assessment of potential causal
association between 2 traits based on the Mendel law that ge-
netic variants are inherited independently, thus providing a
natural RCT.28,29 Initial studies21,30,31 using LDSC regression and
MR analyses reported mixed findings on associations of in-
flammatory markers and MD. None of these studies exam-
ined whether inflammation was associated with specific de-
pressive symptoms.
Using large-scale GWAS data sources, the present study ap-
plied a combination of LDSC regression and MR analyses on
measures of inflammation, as indicated by CRP levels and IL-6
signaling or activity, BMI, as an index of metabolic dysregu-
lation, and 9 specific depressive symptoms. We tested 2 hy-
potheses. First, are the associations between inflammation and
specific depressive symptoms underpinned by a common
genetic basis (ie, coinherited)? Second, is inflammation




This genetic correlation and 2-sample MR study was per-
formed from November 2019 to April 2020. Sample sizes and
characteristics of GWAS data sources20,21,32-39 are listed in
Table 1. They are described in detail in the eMethods in the
Supplement.
Briefly, we included GWAS data sources to maximize
sample sizes yet avoid sample overlap. These data sources
included the following information: serum CRP levels from
204 402 individuals included in the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE)
Inflammation Working Group21; depressive symptoms from
the Neale laboratory39; summary statistics for MD from a
subset (ie, excluding 23andMe participants) of 2 prior Psy-
chiatric Genomics Consortium (PGC) reports20,32 that
Key Points
Question Do inflammatory pathways share a genetic background
with individual depressive symptoms, and do they potentially
causally contribute to them?
Findings Based on large genome-wide association study data
sources, this genetic correlation and 2-sample mendelian
randomization study found genetic overlap between a higher
C-reactive protein (CRP) level, a broad marker of inflammation,
and 9 depressive symptoms; upregulated interleukin-6 signaling, a
major stimulator of CRP, emerged as a potential causal risk factor
for suicidality. Body mass index, but not interleukin 6 or CRP, was
potentially causally associated with 4 other depressive symptoms.
Meaning Interleukin 6 overactivity could be associated with
suicidality; interleukin-6 blockade may be a novel treatment target
that warrants future research.
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respectively include and exclude UK Biobank participants,
resulting in final sample sizes of 500 199 and up to 230 214
individuals (details are given in the eMethods in the Supple-
ment); BMI (up to 322 154 individuals) and height (up to
253 280 individuals) from the Genetic Investigation of
Anthropometric Traits (GIANT) consortium33,34; and soluble
IL-6 receptor (sIL-6R) protein levels from the INTERVAL
study.35 Genome-wide association studies on depressive
symptoms were based on UK Biobank data as assessed in an
online follow-up survey using the self-report Patient Health
Questionnaire 9 (PHQ-9) (up to 117 907 individuals).40,41
The PHQ-9 asks about the presence of 9 depressive symp-
toms, as defined in the DSM-IV (Fourth Edition),42 over the
past 2 weeks (eTable 1 and eTable 2 in the Supplement list
symptom descriptions and frequency statistics in the UK
Biobank sample). Three PHQ-9 symptoms (sleep problems,
changes in appetite, and psychomotor changes) do not dif-
ferentiate between underlying diametrically opposite symp-
toms (eg, insomnia and hypersomnia). Although these
symptoms are included for comprehensiveness of analyses,
we emphasize that any associations specific to one (but not
the other) underlying symptom are likely obscured in analy-
ses. We have included GWAS data for insomnia36 (up to
386 533 individuals) to disentangle associations with sleep
problems to some extent but could not identify GWAS data
for other underlying symptoms.
All original GWAS investigations were conducted with eth-
ics committee approval. The UK Biobank study received ap-
proval from the National Health Service National Research Eth-
ics Service. Written informed consent was obtained from
participants.
LDSC Regression Analysis
Linkage disequilibrium score regression regresses SNV GWAS
χ2 statistics for 1 phenotype (to infer SNV-based heritability)
or χ2 statistics cross products for 2 phenotypes (to infer SNV-
based coheritability) on LDSCs (ie, the sum of a SNV pairwise
squared correlation with other SNVs in a 1cM window43). Ge-
netic correlations between 2 phenotypes can be inferred by the
regression slope.25,26
Table 1. GWAS Data Sources
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Abbreviations: BMI, body mass index; CRP, C-reactive protein; GIANT, Genetic
Investigation of Anthropometric Traits; GWAS, genome-wide association study;
LDSC, linkage disequilibrium score; MD, major depression; MR, mendelian
randomization; NA, not applicable; PGC, Psychiatric Genomics Consortium;
RICOPILI, Rapid Imputation for Consortias Pipeline; sIL-6R, soluble interleukin 6
receptor.
a Exact sample sizes vary per depressive symptom phenotype (minimum,
117 177; median, 117 822; maximum, 117 907) and per single-nucleotide variant
for MD (Wray et al,32 2018) (minimum, 55 795; median, 142 646; maximum,
230 241), BMI (minimum, 50 005; median, 233 524; maximum, 322 154),
insomnia (minimum, 366 461; median, 385 989; maximum, 386 533), and
height (minimum, 50 003; median, 251 631; maximum, 253 280).
b Note that depression was characterized differently among samples in the
study by Howard et al,20 including definitions of broad depression, probable
MD, and MD diagnosis ascertained from hospital records.
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We used LDSC regression to assess the SNV-based herita-
bility (h2) of all phenotypes and the genetic correlations of CRP
levels, MD, BMI, and height with depressive symptoms. For ge-
netic correlations with depressive symptoms, MD and height
served as positive and negative control variables showing
strong and absent associations with depressive symptoms, re-
spectively. European ancestry information from the 1000 Ge-
nomes Project was used as the linkage disequilibrium refer-
ence panel, aligning with European origin of GWAS samples.44
We used the Benjamini-Hochberg method45 to control the false
discovery rate (FDR) across PHQ-9 symptoms for each
phenotype.
2-Sample Mendelian Randomization Analyses
Genetic Instruments
Mendelian randomization uses genetic variants associated with
an exposure as instruments to test for potential causal asso-
ciation of this exposure with an outcome. Genetic instru-
ments were based on functional knowledge of the inflamma-
tory pathway underlying CRP production. C-reactive protein
is produced in the liver as a consequence of upstream IL-6 sig-
naling via membrane-bound IL-6 receptors (IL-6Rs) on
hepatocytes.46 The IL-6Rs also exist in soluble form in the
plasma (sIL-6Rs), but IL-6–sIL-6R complexes are neutralized
under physiological conditions.46-49 Therefore, lower sIL-6R
plasma levels constitute an indirect index of IL-6 signaling.37,49
We used genome-wide statistically significant, indepen-
dent (R2 < 0.1), and strong (F statistics >10)50 genetic instru-
ments for higher CRP levels, IL-6 signaling, and
BMI21,33,35,37,51,52 as summarized in Table 2. In the eMethods
in the Supplement, we describe details for genetic
instrument selection, clumping procedure, comparison with
previous work,31 a functional description of included SNVs, and
the number of SNVs across instruments and analyses
(eTables 3-7 and eFigure 1 in the Supplement). Briefly, we de-
fined 2 main genetic instruments for upregulated CRP levels
and IL-6 signaling using SNVs around CRP (GenBank 1401) and
IL6R (GenBank 3570) genes, respectively, that were associ-
ated with CRP levels based on CRP GWAS summary
statistics.21,51
As alternative approaches and to demarcate associations
of inflammator y activ ity from those of metabolic
dysregulation,53 we defined further genetic instruments for
CRP levels, IL-6 signaling, and BMI. We used SNVs associated
with CRP levels and BMI throughout the genome and SNVs in
the IL6R gene associated with sIL-6R plasma levels, which were
inversed to reflect an indirect marker of IL-6 signaling.
Statistical Analyses
Two-sample MR analyses were performed using R, version
3.6.0 (R Foundation for Statistical Computing) and the
TwoSampleMR package.54,55 Exposure and outcome GWAS
summary statistics were harmonized by aligning summary sta-
tistics to the forward strand if the forward strand was known
or could be inferred. Ambiguous SNVs and SNVs with a non-
inferable forward strand were excluded from analyses.
We first performed fixed-effects meta-analysis of genetic
instruments using inverse-variance weighting (IVW).56 Stan-
dard errors were computed with the Wald estimator and delta
weighting to account for uncertainty in genetic association with
the exposure.57 To assess the robustness of our findings, the
weighted median MR approach was performed, which pro-
vides valid estimates if at least 50% of the MR instrument
weights on the exposure are valid.56,58,59
Table 2. Genetic Instruments for MR Analyses
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Genome-wide 95 NA NA
Abbreviations: BMI, body mass index; chr1, chromosome 1; CRP, C-reactive
protein; GWAS, genome-wide association study; IL-6, interleukin 6; kb, kilobase;
MR, mendelian randomization; NA, not applicable; sIL-6R, soluble interleukin 6
receptor; SNV, single-nucleotide variant; ↑, increasing.
a F statistics were computed using the following approximation:
F = β2 ÷ SE.2,37,52
b Available number of SNVs used is reported here for Patient Health
Questionnaire 9 depressive symptom outcome; however, these differ per
outcome, and exact numbers are listed in eTable 7 in the Supplement.
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To assess horizontal pleiotropy (ie, an association of the
genetic instrument with the outcome independent of the ex-
posure), we tested for the presence of statistically significant
(P < .05) heterogeneity in IVW MR analyses using the Coch-
ran Q statistic.60 We also performed more restrictive MR analy-
ses focusing on SNVs within CRP and IL6R genes (compare gene
loci in Table 2) using MR-Egger estimation for genetic instru-
ments including SNVs throughout the genome, leave-one-
out, and single-SNV MR analyses.58,61,62 Details are available
in the eMethods in the Supplement.
All MR analyses were FDR controlled across PHQ-9 symp-
toms using the Benjamini-Hochberg method.45 Because main
IVW MR analyses for CRP levels and IL-6 signaling focused on
2 genetic instruments, we also corrected these comparisons
with the Bonferroni method.
Availability of Data and Materials
Genome-wide association study data sources are openly avail-
able as GWAS summary statistics and by request for CRP lev-
els from the CHARGE Inflammation Working Group.21 Ge-




Using LDSC regression, we estimated SNV-based heritability
(h2) and genetic correlations of CRP levels,21 BMI,33 MD (based
on work by Wray et al32 as positive control), and height (nega-
tive control)34 with depressive symptoms, MD,20,32 and
insomnia36 (Figure 1). Exact values are listed in eTables 8, 9,
and 10 in the Supplement.
The SNV-based heritability was low for depressive symp-
toms (h2 range = 0.0143-0.0631), MD (h2 range = 0.0599-
0.0723), and CRP levels (h2 = 0.0941), whereas BMI
(h2 = 0.1297) and height (h2 = 0.3120) displayed relatively
higher levels. Of note, h2 for suicidality was slightly below the
suggested threshold of z > 4 (h2 z = 3.97), which could reflect
a potential unreliability of genetic correlation estimates.26
There was evidence for genetic correlations of CRP levels with
all depressive symptoms after FDR correction (genetic corre-
lation range, 0.152-0.362), with the lowest correlation seen for
depressed mood (genetic correlation [SE] = 0.152 [0.056]; FDR
P = .006) and the highest for changes in appetite (genetic cor-
relation [SE] = 0.362 [0.067]; FDR P < .001). C-reactive pro-
tein levels showed small genetic correlations with MD and in-
somnia (eTable 10 in the Supplement). Body mass index
showed a similar pattern of genetic correlations in that the BMI–
depressive symptom estimates were associated with CRP–
depressive symptom estimates (Pearson r = 0.89, P = .001;
Spearman ρ = 0.92, P = .001).
MR Analyses
Mendelian randomization analyses allowed testing of poten-
tial causal association between proinflammatory activity and
depressive symptoms. Figure 2 shows MR analyses for CRP lev-
els, IL-6 signaling, and BMI instruments using IVW
meta-analysis20,32 (exact values are listed in eTable 11 in the
Supplement).
Findings for CRP Levels
Mendelian randomization analyses of the CRP levels instru-
ment did not show evidence for associations with depressive
symptoms, MD, or insomnia (eTable 11 and eTable 12 in the
Supplement). Using the alternative CRP instrument, there was
some evidence for associations of increased CRP levels with
tiredness, changes in appetite, and psychomotor changes
(Table 3),20,32,45 but none of these associations replicated in
weighted median MR (eTable 13 in the Supplement).
Figure 1. Single-nucleotide variant (SNV)–Based Heritability




MD (Howard et al,20 2019) 0.0599





Changes in appetite 0.0497







CRP levels BMI Height MD (Wray et al,32 2018)
The SNV-based heritability coefficients (h2) for major depression (MD) and
depressive symptoms (y-axis) are shown on the z-axis. Sleep problems, changes
in appetite, and psychomotor changes reflect composite symptoms, which may
obscure associations specific to one but not the other underlying symptom
(psychomotor retardation or agitation, increased or decreased weight or
appetite, and insomnia or hypersomnia). The error bars indicate 95% CIs, which
were calculated using Fisher z transformation. Outcomes below the dashed line
are the Patient Health Questionnaire 9 depressive symptoms.
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Findings for IL-6 Signaling
We observed an association of upregulated IL-6 signaling with
suicidality even after conservative FDR and Bonferroni cor-
rections (estimate [SE], 0.035 [0.010]; FDR plus Bonferroni
P = .01) (eFigure 2 in the Supplement), but there were no as-
sociations with MD, insomnia, or other depressive symp-
toms. The IL-6–suicidality association was replicated with the
(indirect) IL-6 signaling instrument and across IVW and
weighted median MR analyses (main IL-6 signaling weighted
median estimate [SE], 0.030 [0.011]; P = .006; alternative IL-6
signaling IVW estimate [SE], 0.002 [0.001]; P = .005; and al-
ternative IL-6 signaling weighted median estimate [SE], 0.002
[0.001]; P = .047) (Table 3 and eTable 12 and eTable 13 in the
Supplement). There was also some evidence in IVW but not
weighted median MR analysis for associations of (indirect) IL-6
signaling with sleep problems, but not with insomnia, sug-
gesting potential association specificity to hypersomnia
(Table 3).
Findings for BMI
In IVW MR analyses, the instrument used for BMI indicated
that higher BMI was associated with anhedonia, tiredness,
changes in appetite, and feelings of inadequacy (estimate [SE],
0.046 [0.012]; FDR P = .001 for anhedonia; estimate [SE], 0.049
[0.018]; FDR P = .02 for tiredness; estimate [SE], 0.121 [0.013];
FDR P < .001 for changes in appetite; and estimate [SE], 0.028
[0.011]; FDR P = .02 for feelings of inadequacy) (Figure 2 and
eTable 11 and eFigure 3 in the Supplement). Except for
Figure 2. Mendelian Randomization Inverse-Variance Weighted (IVW) Associations of Genetic Instruments for Upregulated C-Reactive Protein (CRP)
Levels, Interleukin 6 (IL-6) Signaling, and Higher Body Mass Index (BMI) With Major Depression (MD) and Depressive Symptoms
MR IVW estimate (95% CI)
–0.2–0.4–0.6–0.8–0.1 0 0.2 0.4
Outcome











MD (Wray et al,32 2018)
MR IVW estimate (95% CI)
–0.3 –0.1–0.2–0.4 0 0.1 0.2
MR IVW estimate (95% CI)
–0.1 0 0.20.1
CRP levels IL-6 signaling BMI
Sleep problems, changes in appetite, and psychomotor changes reflect
composite symptoms, which may obscure associations specific to one but not
the other underlying symptom (psychomotor retardation or agitation, increased
or decreased weight or appetite, and insomnia or hypersomnia). The error bars
indicate 95% CIs. Outcomes below the dashed line are the Patient Health
Questionnaire 9 depressive symptoms.
Table 3. MR IVW Estimates of Alternative Genetic Instruments for Upregulated CRP Levels and IL-6 Signaling
Outcome
CRP levels (genome-wide) IL-6 signaling (indirect)
Estimate (SE) P value FDR P valuea Estimate (SE) P value FDR P valuea
MD (Howard et al,20 2019) −0.021 (0.011) .06 NA −0.002 (0.003) .53 NA
MD (Wray et al,32 2018) 0.020 (0.020) .33 NA −0.012 (0.007) .09 NA
Insomnia −0.010 (0.013) .42 NA 0.004 (0.003) .25 NA
Anhedonia 0.002 (0.005) .64 .64 0.000 (0.002) .80 .80
Depressed mood −0.004 (0.005) .45 .58 0.000 (0.001) .72 .80
Sleep problemsb 0.012 (0.008) .16 .29 0.005 (0.002) .01c .06
Tiredness 0.021 (0.007) .002c .02c 0.002 (0.002) .26 .40
Changes in appetiteb 0.012 (0.006) .048c .14 0.001 (0.002) .46 .59
Feelings of inadequacy −0.003 (0.006) .63 .64 −0.002 (0.002) .14 .30
Concentration problems −0.005 (0.005) .34 .51 0.003 (0.002) .06 .19
Psychomotor changesb −0.006 (0.003) .046c .14 0.001 (0.001) .24 .40
Suicidality 0.004 (0.003) .15 .29 0.002 (0.001) .005c .049c
Abbreviations: CRP, C-reactive protein; FDR, false discovery rate; IL-6,
interleukin 6; IVW, inverse-variance weighting; MD, major depression; MR,
mendelian randomization; NA, not applicable.
a P values were FDR controlled across depressive symptoms of each outcome
using the Benjamini-Hochberg method.45
b Sleep problems, changes in appetite, and psychomotor changes reflect
composite symptoms, which may obscure associations specific to one but not
the other underlying symptom.
c P < .05 for nominal and FDR-controlled statistically significant results.
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feelings of inadequacy, these associations persisted in weighted
median MR analyses (estimate [SE], 0.042 [0.016]; P = .007 for
anhedonia; estimate [SE], 0.057 [0.023]; P = .01 for tired-
ness; estimate [SE], 0.141 [0.017]; P < .001 for changes in ap-
petite; and estimate [SE], 0.031 [0.016]; P = .06 for feelings of
inadequacy) (eTable 12 in the Supplement).
Assessment of Horizontal Pleiotropy
Assessing if SNV-outcome associations are mediated via the
exposure and not via other mechanisms (ie, horizontal plei-
otropy) is a key prerequisite for validity of causal inference from
MR analysis. As detailed in the eResults in the Supplement, we
assessed horizontal pleiotropy by measuring between-SNV
heterogeneity (eTable 14 and eTable 15 in the Supplement), and
we performed sensitivity analyses that are more robust to plei-
otropy, including gene-restricted MR, MR-Egger regression, and
MR analyses excluding outlying pleiotropic SNVs (eFigure 4
and eTables 16-20 in the Supplement). The association of IL-6
signaling with suicidality was robust across sensitivity analy-
ses (main IL-6 signaling Cochran Q = 5.77; P = .33; gene-
restricted IVW estimate [SE], 0.027 [0.011]; P = .01). The as-
sociations of higher BMI with anhedonia, tiredness, changes
in appetite, and feelings of inadequacy were directionally con-
sistent in all sensitivity analyses (MR-Egger slope [SE], 0.028
[0.036]; P = .44 for anhedonia; MR-Egger slope [SE], 0.043
[0.056]; P = .45 for tiredness; MR-Egger slope [SE], 0.183
[0.038]; P < .001 for changes in appetite; and MR-Egger slope
[SE], 0.050 [0.033]; P = .14) for feelings of inadequacy.
Discussion
We tested SNV-based genetic correlation and potential MR as-
sociation between proinflammatory activity and individual de-
pressive symptoms. Using LDSC regression, we showed con-
sistent genetic correlations between CRP levels, a sensitive
index of inflammatory activity, and depressive symptoms as
assessed with the PHQ-9. Genetic correlations between CRP
levels and each specific depressive symptom were small and
similar in size (genetic correlation range, 0.152-0.362). Men-
delian randomization analyses for specific depressive symp-
toms showed consistent evidence for associations between
higher IL-6 activity and suicidality. Findings of increased CRP
levels and IL-6 overactivity with other PHQ-9 symptoms were
inconsistent, but there were some indications that IL-6 sig-
naling could be associated with hypersomnia, which requires
replication in future work. Regarding metabolic dysregula-
tion and depressive symptoms, we found consistent MR as-
sociations of higher BMI with anhedonia, tiredness, changes
in appetite, and feelings of inadequacy. However, our MR analy-
ses did not replicate prior research showing MR associations
of CRP levels or IL-6 signaling with MD31 (eDiscussion in the
Supplement).
Inflammation and Suicidality
Suicidality and suicidal behavior have a multifactorial origin,
and identification of causal markers is critical to advance pre-
vention and treatment efforts.64,65 Increased levels of inflam-
matory markers, and IL-6 in particular, have been found to be
associated with suicidality or suicidal behavior, and patients
with chronic inflammatory illnesses, such as inflammatory
bowel disease, exhibit increased suicide rates.66-69 We pro-
vide evidence for an association between higher IL-6 signal-
ing and suicidality. Findings of this association were consis-
tent across LDSC regression and MR analyses using different
genetic proxies for IL-6 signaling.
An association between IL-6 signaling and suicidality may
have important clinical implications. First, suicidality may be-
come a useful symptom (characteristic of inflammatory activ-
ity beyond CRP levels) for stratification efforts in RCTs of im-
munotherapy in depression. Second, it may be informative to
evaluate the symptom-specific effectiveness of immunothera-
pies for depression and for treating suicidality in particular. Rai-
son and colleagues15 demonstrated the symptom-specific ef-
fectiveness of the tumor necrosis factor α inhibitor infliximab
for suicidality (among 4 other symptoms) in patients with MD
with high CRP levels before treatment. Data from available
RCTs of immunotherapies for chronic inflammatory illnesses
and from RCTs of anti–IL-6 and anti–IL-6R drugs in MD17 may
be valuable to further examine symptom-specific immuno-
therapy outcomes. Therefore, our findings emphasize the need
for considering suicidality in immunopsychiatry research and
highlight the clinical potential of immunotherapies, and spe-
cifically IL-6R blockade, for treatment of suicidality.
Inflammation, Metabolic Dysregulation,
and Depressive Symptoms
Apart from suicidality and preliminary indications for hyper-
somnia, results for inflammation and other PHQ-9 depres-
sive symptoms were divergent between LDSC regression, in
which robust genetic correlations between CRP levels and de-
pressive symptoms were found, and MR analyses, in which in-
consistent associations that did not replicate across instru-
ments or statistical models were found (Table 3 and
eTables 11-17 in the Supplement). This dissociation of genetic
correlation and MR results for other PHQ-9 depressive symp-
toms may offer important new insights into the interrelation-
ship between low-grade inflammation, metabolic dysregula-
tion, and depression.
Mendelian randomization associations of higher BMI, but
not of increased inflammatory markers, with anhedonia, tired-
ness, changes in appetite, and feelings of inadequacy suggest
that metabolic dysregulation may underlie the coheritability
of inflammatory activity with these symptoms. In the con-
text of previous results,4,70-72 it is likely that associations with
changes in appetite are specific to increased appetite or hy-
perphagia. Taken together, these results suggest immune and
metabolic factors may constitute separate, symptom-
specific risk factors in depression.
Because depressive symptoms themselves could pro-
mote proinflammatory lifestyle choices, such as an un-
healthy diet and reduced physical activity,73,74 reverse causal
inference needs to be assessed as an alternative or additional
explanation. Future studies need to replicate our results and
should further investigate pleiotropic or residual confound-
ing factors that could explain genetic correlations between CRP
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levels and BMI with depressed mood, concentration prob-
lems, and psychomotor changes. In these studies, symptoms
should ideally be assessed without composite items and based
on multiple symptom indicators.
Strengths and Limitations
We report genetic analyses of inflammatory activity, meta-
bolic dysregulation, and depressive symptoms based on large
GWAS data sources. Our sample size maximizes power for ge-
netic analyses.
This study also has some limitations. First is a lack of granu-
lar information on some depressive symptoms assessed by the
PHQ-9, which does not differentiate between diametrically op-
posite symptoms. Although inclusion of insomnia summary
data helped in providing some preliminary suggestions on as-
sociations between IL-6 and hypersomnia, more detailed in-
vestigations disentangling composite symptoms are needed.
Second, depressive symptoms in the general population
and in patients with MD are likely to exist on a continuum, but
they could also be different with regard to their origin and im-
plications, especially because depressive symptoms are com-
mon and may arise in the general population owing to a vari-
ety of reasons other than depression.75 In future work, MR
analysis of symptoms in patients with MD is required to as-
sess the relevance of our findings for depressive symptoms oc-
curring in the context of MD.
Third, inferences on causality should ideally rely
on multiple types of studies because MR analyses rely on
3 key assumptions that are not always met or completely
testable.57,76 Ohlsson and Kendler77 have advocated triangu-
lation of causality using different study designs, such as MR
and RCTs, which we also support.
Fourth, our IL-6 signaling instrument was weighted on
downstream associations with CRP levels, and it is debat-
able if this approach captures an independent association of
IL-6 signaling. However, the fact that we replicated our
results using an sIL-6R–based instrument supports this
interpretation.
Conclusions
This genetic correlation and 2-sample MR study reports a de-
tailed investigation of inflammatory activity, metabolic dys-
regulation, and specific depressive symptoms using LDSC re-
gression and 2-sample MR analyses of large GWAS data. The
findings suggest small but robust genetic correlations of BMI
and CRP levels with depressive symptoms, and MR associa-
tions show that higher BMI could be a causal risk factor for an-
hedonia, tiredness, changes in appetite, and feelings of inad-
equacy. Regarding proinflammatory processes, IL-6 signaling
may be potentially causally associated with suicidality. This
hypothesis is clinically relevant because symptom expres-
sion of suicidality could help identify patients who will re-
spond to immunotherapy. The findings also suggest that phar-
macological approaches targeting IL-6 signaling may be
valuable for treatment of suicidality, which requires further
research.
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